10-hydroxycamptothecine invisible nano-particle sustained release preparation and preparation method thereof
A technology of hydroxycamptothecin and sustained-release preparations, which is applied in the direction of pharmaceutical formulas, medical preparations containing no active ingredients, medical preparations containing active ingredients, etc., which can solve problems such as increased disease sensitivity and MPS self-injury, and achieve Effects of reduced adsorption, high drug loading rate, and mild conditions
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Publication Date
- 2011-09-28
- Estimated Expiration
- Not applicable · inactive patent
Smart Images
Figure 1 Figure 2 Figure 3
Abstract
Description
technical field
[0001] The invention relates to a new pharmaceutical antitumor drug preparation, in particular to a 10-hydroxycamptothecin (hereinafter referred to as 10-hydroxycamptothecin) invisible nanoparticle slow-release preparation for preventing the growth and recurrence of malignant tumors and its preparation method. Background technique
[0002] 10-Hydroxycamptothecin ((S)-4,9-dihydroxy-4-ethyl-1H-pyrano[3',4':6,7]indolizine[1,2b]quinoline-3, 14-(4H, 12H)-diketone) is a topoisomerase I inhibitor, which can inhibit the enzymatic activity of topoisomerase I and inhibit the participation of topoisomerase in DNA replication, repair, genetic recombination and transcription [1] . 10-Hydroxycamptothecin mainly acts on the DNA synthesis phase, on G 0 Phase cells have no effect on G 1 , G 2 , Has slight lethality to cells in M phase. It has a broad anti-tumor spectrum and no cross-resistance with commonly used anti-tumor drugs. It is mainly used clinically for the ...
Examples
Embodiment 1
[0031] Example 1: Preparation of 10-hydroxycamptothecin stealth nanoparticle sustained-release preparation: Weigh 40 mg of 10-hydroxycamptothecin bulk drug, polylactic acid grafted with polyethylene glycol monomethyl ether with a molecular weight of 10,000 Daltons (mPEG-PLA) 400mg, put it in a beaker and dissolve it with 10ml DMF (N,N-dimethylformamide); 1, 4, and 8 hours to replace the water phase in the bathtub to achieve complete dialysis; freeze-dry the resulting suspension to obtain 10-hydroxycamptothecin invisible nano drug-loaded microspheres, which are sterilized and subpackaged.
[0032] Utilize this method to prepare microsphere process to cause carrier material loss substantially; Simultaneously 10-hydroxycamptothecin itself is insoluble in water, and loss is little; From figure 1 The scanning electron microscope image shows that the particle size of the drug-loaded microspheres is round, the average particle size is 210nm, and the drug-loading capacity is 7.1%. f...
Embodiment 2
[0033] Example 2: Preparation of 10-Hydroxycamptothecin Stealth Nanoparticle Sustained Release Preparation: Weigh 40 mg of 10-Hydroxycamptothecin bulk drug, polylactic acid grafted with molecular weight 35000 Dalton polyethylene glycol monomethyl ether (mPEG-PLA) 400mg, put it in a beaker and dissolve it with 10ml DMF (N,N-dimethylformamide); 1, 4, and 8 hours to replace the water phase in the bathtub to achieve complete dialysis; freeze-dry the obtained suspension, sterilize and subpackage. The particle size of the drug-loaded microspheres is rounded ( Figure 4 ), the average particle size is 230nm, the drug loading capacity is 7.6%, and the average drug release time in vitro can reach more than 30 days.
Embodiment 3
[0034] Embodiment 3: Preparation of 10-hydroxycamptothecin invisible nanoparticle slow-release preparation: Weigh 40 mg of 10-hydroxycamptothecin bulk drug, and use molecular weight of 10000 Dalton polyethylene glycol monomethyl ether grafted poly( Lactic acid-glycolic acid) copolymer (mPEG-PLGA) 400mg, put in the beaker and dissolve with 10ml DMF (N, N-dimethylformamide); The above-mentioned solution is transferred to the dialysis bag of minimum permeability 8000 Dalton, Put it in a water bathtub, and replace the water phase in the bathtub every 1, 4, and 8 hours to complete the dialysis; freeze-dry the obtained suspension, and sterilize it for packaging. The particle size of the drug-loaded microspheres is rounded ( Figure 5 ), the average particle size is 224nm, the drug loading capacity is 7.3%, and the average drug release time in vitro can reach more than 30 days.